

# Luca Gianni

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3531751/luca-gianni-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

148  
papers

27,795  
citations

61  
h-index

161  
g-index

161  
ext. papers

32,554  
ext. citations

9  
avg. IF

6.68  
L-index

#	Paper	IF	Citations
148	Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer.. <i>Npj Breast Cancer</i> , <b>2022</b> , 8, 1	7.8	0
147	Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. <i>Journal of Clinical Oncology</i> , <b>2021</b> , JCO2100896	2.2	3
146	Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 827625	5.3	1
145	Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. <i>Nature Reviews Clinical Oncology</i> , <b>2021</b> ,	19.4	56
144	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 1529-1541	59.2	108
143	Multidrug regimens for treatment of older patients with metastatic pancreatic cancer. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 117-121	3.3	0
142	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 1139-1150	21.7	24
141	Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5096-5108	12.9	2
140	Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 99, 102225	14.4	2
139	Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 85, 641-650	3.5	5
138	Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial. <i>Anticancer Research</i> , <b>2019</b> , 39, 797-802	2.3	
137	Event-free survival analysis of the prospectively randomized phase III ETNA study with neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) followed by anthracycline regimens in women with HER2-negative high-risk breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 515-515	2.2	7
136	Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 527-527	2.2	2
135	Adjuvant vemurafenib in resected, BRAF mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 510-520	21.7	123
134	Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas. <i>ESMO Open</i> , <b>2018</b> , 3, e000303	6	9
133	Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 413-423	18.8	98
132	Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 679-697	8.7	8

131	Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 249-256	21.7	89
130	Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, 302-308	13.4	74
129	Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2018</b> , 3, 691-697	18.8	31
128	A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. <i>European Journal of Cancer</i> , <b>2018</b> , 102, 95-102	7.5	32
127	Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1059-1059	2.2	30
126	Demethylating agents to upregulate HLAs and antigen presenting machinery (APM) related genes in HER2+ breast cancer (BC) cell lines.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e13012-e13012	2.2	
125	The GATTO study: A phase I of the anti-MUC1 Gatipotuzumab (GAT) in combination with the anti-EGFR Tomuzotuximab (TO) in patients with EGFR positive solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS2596-TPS2596	2.2	
124	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 27-39 <sup>1-7</sup>	41.7	413
123	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1818-1831	8.9	73
122	Is there room for another HER2-targeting drug?. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 847-849	21.7	3
121	11 yearsPfollow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. <i>Lancet, The</i> , <b>2017</b> , 389, 1195-1205	40	486
120	Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. <i>Breast Cancer Research</i> , <b>2017</b> , 19, 16	8.3	52
119	Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2 Breast Cancer. <i>Cancer Research</i> , <b>2017</b> , 77, 3280-3292	10.1	51
118	Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 732-742	21.7	289
117	HER2-positive breast cancer. <i>Lancet, The</i> , <b>2017</b> , 389, 2415-2429	40	351
116	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two	7.5	21
115	Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 290-6	8.7	25
114	Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience. <i>Breast Cancer Research and Treatment</i> , <b>2016</b> , 155, 127-32 <sup>4-4</sup>	4.4	6

113	Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 702-10	6.1	83
112	Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 337-45	12.9	43
111	Introduction and background biology <b>2016</b> , 1-13		
110	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. <i>Nature Reviews Clinical Oncology</i> , <b>2016</b> , 13, 674-690	19.4	1246
109	5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 791-800	21.7	408
108	Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2158-65	2.2	20
107	Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1136-42	2.2	46
106	Pathological complete response in breast cancer--authorsPreply. <i>Lancet, The</i> , <b>2015</b> , 385, 114-5	40	2
105	Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1003-1003	2.2	81
104	Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 505-505	2.2	14
103	Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 512-512	2.2	6
102	Use of formalin-fixed paraffin-embedded samples for gene expression studies in breast cancer patients. <i>PLoS ONE</i> , <b>2015</b> , 10, e0123194	3.7	9
101	Strategies for clinical development of monoclonal antibodies beyond first-in-man trials: Tested doses and rationale for dose selection.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3040-3040	2.2	
100	Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. <i>Lancet, The</i> , <b>2014</b> , 384, 164-72	40	2177
99	Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 580-91	21.7	359
98	Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 640-7	21.7	313
97	The immune system and response to HER2-targeted treatment in breast cancer. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, e58-68	21.7	171
96	BOLERO-3 results: pharmacological activity or pharmacokinetic effect?--authorsPreply. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, e304-5	21.7	1

95	Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2014</b> , 32, 1188-96	4.3	16
94	Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1437-44	2.2	63
93	Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 511-21	12.9	143
92	Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2159-65	2.2	164
91	Hallmarks of triple negative breast cancer emerging at last?. <i>Cell Research</i> , <b>2014</b> , 24, 904-5	24.7	39
90	Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer. <i>Breast Cancer Research</i> , <b>2014</b> , 16, R58	8.3	37
89	Accurate data processing improves the reliability of Affymetrix gene expression profiles from FFPE samples. <i>PLoS ONE</i> , <b>2014</b> , 9, e86511	3.7	8
88	Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014). <i>Ecancermedicalscience</i> , <b>2014</b> , 8, 433	2.7	11
87	An immune-related signature for prediction of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 530-530	2.2	
86	2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. <i>Lancet, The</i> , <b>2013</b> , 382, 1021-8	4.0	377
85	AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1719-25	2.2	211
84	Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 1236-43	4.3	15
83	Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1954-60	2.2	28
82	Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. <i>Breast Cancer Research</i> , <b>2013</b> , 15, R86	8.3	33
81	Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 503-503	2.2	9
80	Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 505-505	2.2	25
79	Introduction and Background Biology <b>2013</b> , 1-12		
78	Freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by CMF as adjuvant or primary systemic therapy: 10-yr results of a randomized phase III European Cooperative Trial in Operable Breast Cancer (ECTO).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 537-537	2.2	

77	Proliferation-, estrogen-, and T-cell-related metagenes to predict outcome after adjuvant/neoadjuvant chemotherapy for operable breast cancer in the ECTO trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 1014-1014	2.2	2
76	Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. <i>Breast</i> , <b>2012</b> , 21, 507-13	3.6	20
75	Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 25-32	21.7	1438
74	Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1594-600	2.2	189
73	Trastuzumab emtansine for HER2-positive advanced breast cancer. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 1783-91	59.2	2378
72	A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer. <i>Clinical Breast Cancer</i> , <b>2012</b> , 12, 167-74	3	5
71	Cardiac safety in a phase II study of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as adjuvant or neoadjuvant therapy for early-stage HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 532-532	2.2	2
70	Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, LBA1-LBA1	2.2	13
69	Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, LBA1-LBA1	2.2	31
68	Treatment of HER2-positive breast cancer: current status and future perspectives. <i>Nature Reviews Clinical Oncology</i> , <b>2011</b> , 9, 16-32	19.4	606
67	Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. <i>Lancet Oncology, The</i> , <b>2011</b> , 12, 236-44	21.7	500
66	Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 125, 447-55	4.4	128
65	Surrogate markers for targeted therapy-based treatment activity and efficacy. <i>Journal of the National Cancer Institute Monographs</i> , <b>2011</b> , 2011, 91-4	4.8	2
64	Triple-negative breast cancer: an unmet medical need. <i>Oncologist</i> , <b>2011</b> , 16 Suppl 1, 1-11	5.7	542
63	International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , <b>2011</b> , 2011, 147-51	4.8	55
62	Pertuzumab [a HER-2 Dimerisation Inhibitor [for the Treatment of Breast and Other Cancers <b>2011</b> , 73-90		
61	Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. <i>Cancer Research</i> , <b>2010</b> , 70, 8852-62	10.1	49
60	Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1181-7	2.2	135



59	Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4554-61	2.2	43
58	Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 1138-44	2.2	496
57	Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4316-23	2.2	163
56	Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. <i>Lancet. The</i> , <b>2010</b> , 375, 377-84	40	864
55	Triple-negative breast cancer: disease entity or title of convenience?. <i>Nature Reviews Clinical Oncology</i> , <b>2010</b> , 7, 683-92	19.4	588
54	Role of anthracyclines in the treatment of early breast cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4798-808	2.2	71
53	Reply to S.M. Ali et al. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, e274-e275	2.2	1
52	Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 2474-81	2.2	152
51	Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. <i>Nature Clinical Practice Oncology</i> , <b>2009</b> , 6, 93-104		68
50	Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1685-93	2.2	81
49	Never use anthracyclines with trastuzumab: it is time to reconsider the taboo. <i>Breast Cancer Research and Treatment</i> , <b>2009</b> , 117, 599-601	4.4	4
48	Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours. <i>BJU International</i> , <b>2009</b> , 104, 340-6	5.6	26
47	State of the art of adjuvant therapy. <i>European Journal of Cancer, Supplement</i> , <b>2008</b> , 6, 27-30	1.6	
46	The "other" signaling of trastuzumab: antibodies are immunocompetent drugs. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 1778-80	2.2	15
45	Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 814-9	2.2	287
44	Anthracycline cardiotoxicity. <i>Topics in Current Chemistry</i> , <b>2008</b> , 283, 21-44		21
43	Abstract LB-302: A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors <b>2008</b> ,		5
42	The Choice of the Correct Imaging Modality in Breast Cancer Management <b>2008</b> , 281-292		

41	Targeting TRAIL agonistic receptors for cancer therapy. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 2313-7	12.9	64
40	Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes. <i>Cardiovascular Toxicology</i> , <b>2007</b> , 7, 67-71	3.4	94
39	Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2007</b> , 320, 790-800	4.7	31
38	Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 10990-1001	5.4	75
37	Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2006</b> , 318, 424-33	4.7	53
36	The cost of life: should it matter to doctors?. <i>Annals of Oncology</i> , <b>2006</b> , 17, 357-8	10.3	2
35	Capecitabine/Cyclophosphamide/Methotrexate for patients with metastatic breast cancer: a dose-finding, feasibility, and efficacy study. <i>Clinical Breast Cancer</i> , <b>2006</b> , 7, 321-5	3	4
34	Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. <i>European Journal of Cancer</i> , <b>2006</b> , 42, 171-8	7.5	35
33	30 years follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. <i>BMJ, The</i> , <b>2005</b> , 330, 217	5.9	195
32	Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. <i>European Journal of Cancer</i> , <b>2005</b> , 41, 1746-50	7.5	121
31	Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. <i>New England Journal of Medicine</i> , <b>2005</b> , 353, 1659-72	59.2	3921
30	Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 7265-77	2.2	461
29	Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 8715-21	12.9	135
28	Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 1867-74	2.2	148
27	Technology insight: Emerging techniques to predict response to preoperative chemotherapy in breast cancer. <i>Nature Clinical Practice Oncology</i> , <b>2004</b> , 1, 44-50		19
26	Clinical relevance of different sequencing of doxorubicin and cyclophosphamide, methotrexate, and Fluorouracil in operable breast cancer. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 1614-20	2.2	102
25	Future options with trastuzumab for primary systemic and adjuvant therapy. <i>Seminars in Oncology</i> , <b>2004</b> , 31, 51-7	5.5	42
24	Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa) is independent of EGFR expression level. <i>Journal of Cellular Physiology</i> , <b>2004</b> , 198, 259-68	7	91



23	Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. <i>Pharmacological Reviews</i> , <b>2004</b> , 56, 185-229	22.5	2619
22	Cardiotoxic effects of anthracycline-taxane combinations. <i>Expert Opinion on Drug Safety</i> , <b>2003</b> , 2, 59-71	4.1	19
21	International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 2600-8	2.2	276
20	Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 5944-51	12.9	37
19	The future of targeted therapy: combining novel agents. <i>Oncology</i> , <b>2002</b> , 63 Suppl 1, 47-56	3.6	21
18	Mechanism-based pharmacokinetic model for paclitaxel. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 4065-73	2.2	118
17	Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy. <i>Investigational New Drugs</i> , <b>2001</b> , 19, 179-96	4.3	20
16	Adjuvant and neoadjuvant treatment of breast cancer. <i>Seminars in Oncology</i> , <b>2001</b> , 28, 13-29	5.5	14
15	Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 329-35	2.2	133
14	Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 2222-31	2.2	35
13	Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 37-43	2.2	148
12	Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients. <i>Anti-Cancer Drugs</i> , <b>2000</b> , 11, 331-7	2.4	44
11	New active drugs in the treatment of lymphomas. <i>Current Opinion in Oncology</i> , <b>1994</b> , 6, 480-8	4.2	2
10	Learning from CI-941 about pharmacokinetically guided dose escalation. <i>European Journal of Cancer</i> , <b>1992</b> , 28A, 1302-4	7.5	3
9	Primary and salvage chemotherapy in advanced Hodgkin's disease: the Milan Cancer Institute experience. <i>Annals of Oncology</i> , <b>1991</b> , 2 Suppl 1, 9-16	10.3	59
8	Cisplatin and cyclophosphamide in advanced ovarian carcinoma: activity and toxicity of an ambulatory regimen. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>1990</b> , 13, 199-203	2.7	3
7	Monoclonal antibodies against doxorubicin. <i>International Journal of Cancer</i> , <b>1988</b> , 42, 798-802	7.5	14
6	Four-drug sequential regimen in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>1987</b> , 10, 151-7	4.4	3

5	Differences in O <sub>2</sub> reduction by the iron complexes of adriamycin and daunomycin: the importance of the sidechain hydroxyl group. <i>Biochimica Et Biophysica Acta - General Subjects</i> , <b>1986</b> , 884, 326-36	4	52
4	Hydroxyl radical production and DNA damage induced by anthracycline-iron complex. <i>FEBS Letters</i> , <b>1984</b> , 172, 226-30	3.8	119
3	Oxidative destruction of DNA by the adriamycin-iron complex. <i>Biochemistry</i> , <b>1984</b> , 23, 928-36	3.2	155
2	Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex. <i>Biochemistry</i> , <b>1982</b> , 21, 1707-12	3.2	219
1	Cardiovascular Toxicity of Antitumor Drugs: Translating Molecular Mechanisms into Clinical Facts	223-256	